ライフサイエンスコーパス: tolerogenic

1 al DC activation states, from immunogenic to tolerogenic.

2 responses, also acts on DCs, rendering them tolerogenic.

3 promote tumor progression by rendering them tolerogenic.

4 cell life span in the periphery and is thus tolerogenic.

5 nability of MSCs from ITP patients to induce tolerogenic ability in DCs.

6 This presumed tolerogenic action turned out to be a sensitization proc

7 Whereas intact VCAN exerts tolerogenic activities through Toll-like receptor 2 (TLR

8 om CCR2 mice failed to be mobilized and lost tolerogenic activity in vivo, but sustained suppressive

9 main of the alpha-chain is necessary for the tolerogenic activity of C4BP(beta(-)).

10 th a crucial role of p38alpha to program the tolerogenic activity of CD103(+) DCs, such DC subset con

11 tumor growth, affected the accumulation and tolerogenic activity of MDSCs in tumors, and inhibited t

12 ritic cell (DC) function from immunogenic to tolerogenic activity.

13 lated the in vivo switch from immunogenic to tolerogenic activity.

14 he intake of probiotic Lactococcus lactis as tolerogenic adjuvant (combined therapy).

15 tiation and is able to promote a distinctive tolerogenic and anti-inflammatory profile on monocyte-de

16 We compared the tolerogenic and antidiabetogenic properties of CD11c pro

17 mmune response but also need to overcome the tolerogenic and immunosuppressive microenvironments that

18 Interestingly, tolerogenic and mature DCs manifested substantially diff

19 At the level of glycolysis, tolerogenic and mature DCs showed similar glycolytic rat

20 consistent with the notion that FVIII-PS is tolerogenic and suggest that immunization with this tole

21 sets differing susceptibility to the in vivo tolerogenic anti-CD3-mediated modulation.

22 The tolerogenic anti-CD3epsilon monoclonal Abs (anti-CD3) ar

23 rgeting the CD45 tyrosine phosphatase with a tolerogenic anti-CD45RB mAb acutely increases Treg numbe

24 KIM-1-mediated phagocytosis leads to pro-tolerogenic antigen presentation, which suppresses CD4 T

25 egs from a variety of human monocyte-derived tolerogenic antigen-presenting cells in current developm

26 toli cells, can function as non-professional tolerogenic antigen-presenting cells, and sustain the bl

27 uires reactivation following exposure to the tolerogenic antigen.

28 ation, we investigated whether enrichment of tolerogenic APCs (tolAPCs) in donor corneas can enhance

29 the gut microbiota, as well as induction of tolerogenic APCs, which led to reduced activation of dia

30 ve HDAC6 inhibitor disrupts this STAT3/IL-10 tolerogenic axis points to HDAC6 as a novel molecular ta

31 o overcome these limitations, we generated a tolerogenic bacterial delivery technology based on live

32 eting of glycolysis can convert conventional tolerogenic cancer cell death stimuli into immunogenic o

33 tiple treatments of TSG-6 rendered APCs more tolerogenic, capable of enhancing Treg generation and de

34 itions and may contribute to the homeostatic tolerogenic capacity of DCs.

35 In this study, we analyzed the tolerogenic capacity of IL-10-modulated DC (IL-10DC) sub

36 ted from an imbalance between the numbers of tolerogenic CD103(+) and PDCA1(+) plasmacytoid dendritic

37 e immunomodulatory responses, frequencies of tolerogenic CD103(+) and plasmacytoid dendritic cells we

38 proportions of Foxp3(+) regulatory T cells, tolerogenic CD103(+) dendritic cells, and less Il10 gene

39 ic cells (DCs), whereas UV-Ct accumulated in tolerogenic CD11b(-)CD103(+) DCs.

40 Subsequently, induction of tolerogenic CD11c(+) DCs leads to the generation of hapt

41 effect was mediated through the induction of tolerogenic CD11C(+)CD8alpha(-) dendritic cells (DCs) an

42 ing, which in turn promote the generation of tolerogenic CD14(+) CD11c(+) dendritic cells characteriz

43 DCIR2(+) DCs but not DEC-205(+) DCs elicited tolerogenic CD4(+) T-cell responses in NOD mice.

44 associated with inadequate reconstitution of tolerogenic CD4(+)CD25(+)FOXP3(+) regulatory T cells (Tr

45 Tolerogenic CD8(+) DCs induced the development of tolero

46 ell response, as evidenced by a reduction of tolerogenic CD8+CD122+ T cells and an increase of cytoto

47 findings further define eTACs as a distinct tolerogenic cell population in secondary lymphoid organs

48 et al. (2013) show that eTACs are a distinct tolerogenic cell population that functionally inactivate

49 Recent studies examining tolerogenic cell populations of the intestinal mucosa hi

50 findings, we speculate that AMPs maybe a pro-tolerogenic cellular therapeutic that could have clinica

51 sonins in determining the immunogenic versus tolerogenic characteristics of self antigens.

52 lacking Gal-1 interrupted the Gal-1-mediated tolerogenic circuit and reinforced T cell-dependent anti

53 We identify a novel tolerogenic circuit encompassing suppressive CD1c(+) DCs

54 isplaying both Ag and CD22 ligands induces a tolerogenic circuit resulting in apoptosis of the Ag-rea

55 may influence T. cruzi infection by fueling tolerogenic circuits that hinder anti-parasite immunity.

56 a failure in the activation of Gal-1-driven tolerogenic circuits, otherwise orchestrated by WT dendr

57 developmentally linked and GITR can subvert tolerogenic conditions to boost Th9 immunity.

58 o mature naive cells after stimulation under tolerogenic conditions.

59 response and not by T cells activated under tolerogenic conditions.

60 n CD4(+) T cells under inflammatory, but not tolerogenic, conditions, ICOS emerges as a pivotal effec

61 e sensing of myeloma tumors and modulate the tolerogenic consequences of intact VCAN accumulation.

62 ining peripheral Ags to LECs, which maintain tolerogenic cross-presentation of such Ags.

63 A more aggressive approach involving tolerogenic cytokine administration and/or lymphocyte de

64 cell proliferation but higher levels of the tolerogenic cytokine IL-10 and the Th1 cytokine IFN-gamm

65 The tolerogenic cytokine IL9 promotes T regulatory cell func

66 n of monocyte-derived dendritic cells with a tolerogenic cytokine profile.

67 suppressive Treg-specific cytokine and as a tolerogenic cytokine that efficiently inhibits alloreact

68 In contrast to the production of tolerogenic cytokines (IL-4 and IL-10) in the recipients

69 d with DC expression of inflammatory but not tolerogenic cytokines by inhibiting gene transcription t

70 ) regulatory T cells (Treg cells) expressing tolerogenic cytokines.

71 o be necessary and sufficient for GC-induced tolerogenic DC generation.

72 L-23), with no increase in the expression of tolerogenic DC genes.

73 This tolerogenic DC phenotype and function was marked by a ne

74 ore, the scientific rationale for the use of tolerogenic DC therapy in the fields of allergies, autoi

75 AhR pathway in maintaining IDO expression in tolerogenic DC.

76 rapy showed an increase in induced Tregs and tolerogenic DCs accompanied by the downregulation of the

77 ective immunoregulatory circuit encompassing tolerogenic DCs and forkhead box P3(+) Treg cells that c

78 Inhibition of FAO prevented the function of tolerogenic DCs and partially restored T cell stimulator

79 toimmunity via the induction of skin-derived tolerogenic DCs and Tregs.

80 ized the transcriptional networks induced in tolerogenic DCs by Act-A-iTreg cells.

81 Interestingly, the induction of tolerogenic DCs by PSMs appeared to be independent of mF

82 e graft, demonstrating that TGF-beta-induced tolerogenic DCs can provide an effective means to restor

83 Functionally, tolerogenic DCs demonstrated the highest mitochondrial o

84 unced proinflammatory program of mature DCs, tolerogenic DCs displayed a markedly augmented catabolic

85 firm the importance of BLIMP1 in maintaining tolerogenic DCs in both mice and humans.

86 tion analysis revealed that the education of tolerogenic DCs might involve a direct interaction with

87 Overall, tolerogenic DCs show metabolic signatures of increased o

88 Adding TGF-beta-conditioned tolerogenic DCs to the grafted islets led to long-term s

89 om ITP patients induced mature DCs to become tolerogenic DCs, whereas unmodulated MSCs had no effect.

90 ogeneity was observed among various types of tolerogenic DCs, with ANXA1, Complement component 1 (C1Q

91 and FAO activity was significantly higher in tolerogenic DCs.

92 capacity and reserve were more pronounced in tolerogenic DCs.

93 neutrophils, resulting in an upregulation of tolerogenic DCs.

94 rough which ATRA promotes the development of tolerogenic DCs.

95 ir immunosuppressive effect on DCs, creating tolerogenic DCs.

96 omplexes were significantly more abundant in tolerogenic DCs.

97 ative vaccination using alloantigen-bearing "tolerogenic" DCs.

98 er corroborates the potential of prospective tolerogenic DEC205(+) DC vaccination to interfere with a

99 s of intestinal T-regulatory cell (Treg) and tolerogenic dendritic cell subsets.

100 nistration of autologous (recipient-derived) tolerogenic dendritic cells (ATDCs) is under clinical ev

101 ation with TLR2 ligand from S. aureus induce tolerogenic dendritic cells (DCs) characterized by the p

102 found that both human and mouse SIgA induce tolerogenic dendritic cells (DCs) following binding to s

103 Tolerogenic dendritic cells (DCs) have emerged as releva

104 ulatory T (Treg) cells through generation of tolerogenic dendritic cells (DCs) in an allergic airways

105 ), which may contribute to the generation of tolerogenic dendritic cells (DCs) in the liver.

106 t because adoptive transfer of G-CSF-induced tolerogenic dendritic cells (DCs) promotes Treg accumula

107 Treg-inducing tolerogenic dendritic cells (DCs) were further necessary

108 g has recently been tied to the emergence of tolerogenic dendritic cells (DCs).

109 s and facilitated their differentiation into tolerogenic dendritic cells (DCs; GM-CSF-induced bone ma

110 Tolerogenic dendritic cells (TolDCs) are one such therap

111 Tolerogenic dendritic cells (tolDCs) may offer an intere

112 CD43 between immunogenic dendritic cells and tolerogenic dendritic cells appears to contribute to the

113 Neither regulatory B cells nor tolerogenic dendritic cells contributed to immunosuppres

114 der homeostatic conditions, CD4(+) Tregs and tolerogenic dendritic cells function to maintain mucosal

115 (+) T cells (CD4(+) T cells coincubated with tolerogenic dendritic cells pulsed with the main peanut

116 e intestinal microbiome, mechanisms by which tolerogenic dendritic cells take up antigen, and regulat

117 Tolerogenic dendritic cells were differentiated in the p

118 roach combining administration of autologous tolerogenic dendritic cells with short-term treatment wi

119 een Ig-like transcript 3 (ILT3), a marker of tolerogenic dendritic cells, also known as LILRB4/LIR5/C

120 ns that is characterized by the induction of tolerogenic dendritic cells, an increase in regulatory T

121 regulatory B cells, regulatory macrophages, tolerogenic dendritic cells, and myeloid-derived suppres

122 e phenotype and function of 3 types of RMCs, tolerogenic dendritic cells, suppressor macrophages, and

123 peated antigen exposure or in vitro by using tolerogenic dendritic cells.

124 cells, but it has no effect on migration of tolerogenic dendritic cells.

125 ng tissue emigration of immunogenic, but not tolerogenic, dendritic cells, providing an additional me

126 Induction of these tolerogenic DN1-derived tDCs and the ensuing expansion o

127 ctive is to develop an adoptive therapy with tolerogenic donor-specific type 1 T regulatory cells for

128 E-prostanoid receptors 2 and 4 prevented the tolerogenic effect induced by seminal plasma on the phen

129 We have previously demonstrated that the tolerogenic effect mediated by CD8(+)CD45RC(low) regulat

130 CD8alpha(-) beta(-) pDCs were shown to have tolerogenic effects in experimentally induced allergic a

131 t insight into the mechanisms underlying the tolerogenic effects of B10 cells in EAMG.

132 r, the results provide new insights into the tolerogenic effects of costimulatory blockade and identi

133 The tolerogenic effects of NK1.1(+) cells are mediated throu

134 itional intragraft delivery of Tregs induced tolerogenic effects selective to islet alloantigens.

135 These tolerogenic effects were shown to be mediated by the gen

136 l epitopes in FVIII and possible targets for tolerogenic efforts.

137 reprogrammed myeloid cells not only create a tolerogenic environment by blocking T cell functions and

138 The liver is a tolerogenic environment exploited by persistent infectio

139 The unusual immune repertoire and tolerogenic environment of the liver may explain why thi

140 The liver maintains a tolerogenic environment to avoid unwarranted activation

141 instead, an enhancement of the intrahepatic tolerogenic environment was observed.

142 peripheral tissues upon exposure to Ag in a tolerogenic environment.

143 onal under lymphopenic conditions, even in a tolerogenic environment.

144 and generates a long-lived, antigen-specific tolerogenic environment.

145 cytokines (IL-10, TGF-beta1, and IL-2) and a tolerogenic enzyme (IDO) in bone marrow-derived dendriti

146 Incorporation of gene therapy to drive tolerogenic expression of antigens is a promising strate

147 uire TMEM176B to cross-present antigens in a tolerogenic fashion.

148 ocal tumor-associated DC populations exhibit tolerogenic features by promoting Treg development; howe

149 The dual tolerogenic features that Sia-antigen imposed on DCs are

150 ghest degree of phosphorylation was the most tolerogenic following retreatment with LOS or whole bact

151 enic and suggest that immunization with this tolerogenic form of the protein could be a useful treatm

152 d proinflammatory CD3+CD4+IL-17+ and reduced tolerogenic Foxp3+ Treg lymphocytes (Tregs).

153 The tolerogenic function of intestinal DCs was tested by ado

154 a/TLRs and evaluated the role of TLR4 on the tolerogenic function of intestinal dendritic cells (DCs)

155 OS(-/-) mice exhibited near complete loss of tolerogenic function, despite sustained Arg-1 activity.

156 at IFN-gamma signaling in DCs mediates their tolerogenic function.

157 d neurodegenerative microglia had lost their tolerogenic function.

158 stimulated DCs, favoring the development of tolerogenic functions and finally resulting in T-cell to

159 tiviral immunity, exhibit proinflammatory or tolerogenic functions depending on the context, yet thei

160 We discuss how the counter-regulatory and tolerogenic functions of IDO can be targeted for cancer

161 te DC responses and endow them with enhanced tolerogenic functions.

162 of oral tolerance to DNFB through licensing tolerogenic gut DCs.

163 veal that hCPC in allogeneic settings have a tolerogenic immune behavior, promoting a contact PD-L1-d

164 e located in the healthy epidermis and exert tolerogenic immune functions.

165 The liver provides a tolerogenic immune niche exploited by several highly pre

166 ibit long-term survival in vivo and prompt a tolerogenic immune response characterized by elevated IL

167 her treatment with oral insulin can induce a tolerogenic immune response in children genetically susc

168 These data show that a pre-existing tolerogenic immune response to allergen can affect subse

169 of allergic diseases entails an ineffective tolerogenic immune response to allergens.

170 e in the induction of immunogenic as well as tolerogenic immune responses.

171 he immune response, inducing inflammatory or tolerogenic immunity, dependent on their activation stat

172 igen-specific regulatory T cells (Tregs) and tolerogenic immunity.

173 ing either protein or peptide antigens and a tolerogenic immunomodulator, rapamycin, to induce durabl

174 In conclusion, GMCSF-NAg was tolerogenic in CFA-primed proinflammatory environments b

175 erance and that iTreg are substantially more tolerogenic in this setting.

176 rent pathways of activation, immunogenic and tolerogenic, induce different changes in the lipid compo

177 homa cells by anti-KIR antibodies prevents a tolerogenic interaction and augments NK-cell spontaneous

178 f fetal tolerance, it is not known how these tolerogenic leukocytes are induced.

179 n 9 in mouse and human PDA, which results in tolerogenic macrophage programming and adaptive immune s

180 rface MHC class II (MHCII) and promoting the tolerogenic markers, programmed death-ligand (PD-L)1, PD

181 s article, we report that proteolysis of the tolerogenic matrix proteoglycan versican (VCAN) strongly

182 H)2D3], is able to promote the generation of tolerogenic mature dendritic cells (mDCs) with an impair

183 s, any cell could, in principle, invoke this tolerogenic mechanism for cell surface Ags.

184 We speculate that this tolerogenic mechanism is a contributing factor in DST an

185 Therefore, we propose the tolerogenic mechanism of action of sCD83 to be dependent

186 ecently developed therapeutics that overcome tolerogenic mechanisms activate tumour-directed CTLs and

187 The underlying tolerogenic mechanisms are incompletely understood.

188 deletion and anergy are likely components of tolerogenic mechanisms in the lung, increasing evidence

189 We hypothesized that similar tolerogenic mechanisms prevent their rejection.

190 Among the tolerogenic mechanisms, the expression of the enzyme IDO

191 regulatory T cells (Tregs) in the underlying tolerogenic mechanisms.

192 arcinogenic inflammation and contribute to a tolerogenic microenvironment in tumors.

193 iver is an immunoregulatory organ in which a tolerogenic microenvironment mitigates the relative "str

194 Airway epithelial cells mount a tolerogenic microenvironment that reduces the proinflamm

195 Islet CCL22 expression thus produces a tolerogenic milieu through the interplay of Tregs, invar

196 rexpression alone is sufficient to promote a tolerogenic mode of function in DCs.

197 ation, and to generate immune responses in a tolerogenic model of chronic infection, indicates that V

198 bitory capacities through the involvement of tolerogenic molecules (HLA-G, TGF-beta, and IL-10) were

199 analyzed the expression of costimulatory and tolerogenic molecules by pulmonary CD1c(+) DCs from pati

200 ls such as myeloid-derived suppressor cells, tolerogenic monocytes, and T regulatory cells.

201 Tolerogenic nanoparticle therapy represents a potential

202 Adjunct therapy with tolerogenic nanoparticles represents a novel and broadly

203 Treatment with tolerogenic nanoparticles results in the inhibition of C

204 Intravenous co-administration of tolerogenic nanoparticles with pegylated uricase inhibit

205 it is in humans due at least in part to the tolerogenic nature of the liver.

206 Tregs and, therefore, may play a role in the tolerogenic nature of the liver.

207 ogenic CD8(+) DCs induced the development of tolerogenic NKT cells with a marked T helper 2 cell bias

208 the immune environment, pDCs exhibit either tolerogenic or immunogenic properties.

209 Dendritic cells (DCs) promote either tolerogenic or immunogenic T cell responses, the latter

210 Thus, DCs modulate their ability to prime tolerogenic or immunogenic T cells by expressing a core

211 The mucosal immune system is a unique tolerogenic organ that provides a physiological approach

212 Thus, using APL as a model, we uncover a tolerogenic pathway that may represent a relevant immuno

213 protein by ~90%, disrupting immunogenic and tolerogenic pathways to different degrees.

214 downregulates TH2 immune responses, induces tolerogenic pathways, and increases regulatory T cells.

215 zation to food fails to stimulate protective tolerogenic pathways, leading to the development of the

216 ly reprograms dendritic cells (DCs) toward a tolerogenic phenotype and induces regulatory T cells (Tr

217 marrow-derived DCs to Zn in vitro induced a tolerogenic phenotype by diminishing surface MHC class I

218 ation and differentiation of DCs by inducing tolerogenic phenotype by modulating the expression of PD

219 ight into the mechanisms of the TLR4-induced tolerogenic phenotype in human DCs, which can help the b

220 grafts, suggesting a high incidence of a pro-tolerogenic phenotype in stable patients on chronic immu

221 The mechanisms by which Zn regulates the tolerogenic phenotype of DCs remain largely unknown.

222 ophages and dendritic cells (DCs) promotes a tolerogenic phenotype reversed by PAFR-antagonists treat

223 GRO-gamma-treated MDSCs had a tolerogenic phenotype that was characterized by an incre

224 s process was dependent on IFN-gamma and the tolerogenic phenotype was conferred by IDO.

225 rhans and myeloid dendritic cells) exhibit a tolerogenic phenotype, despite constant exposure to dang

226 DC-RAs displayed a mature yet tolerogenic phenotype, expressing IL-10, TGF-beta, IL-27

227 um from women with endometriosis exhibited a tolerogenic phenotype, including increased IL-10 product

228 neously, KCs lose signature markers of their tolerogenic phenotype.

229 ion in IFN-gamma-treated DCs, resulting in a tolerogenic phenotype.

230 phageal adenocarcinoma cell lines, display a tolerogenic phenotype.

231 ndritic cell surface, driving them to a more tolerogenic phenotype.

232 of pathogenic effector T cells toward a more tolerogenic phenotype.

233 Thus, Zn shapes the tolerogenic potential of DCs in vitro and in vivo and pr

234 cation as a chemical tool to investigate the tolerogenic potential of Siglec-G.

235 biting the development of MHCII(low) DC with tolerogenic potential.

236 induce autoimmune diabetes, indicating their tolerogenic potential.

237 onversion to a regulatory lineage and favour tolerogenic presentation of antigens to naive CD4(+) T c

238 However, tolerogenic processes remain poorly understood, and stra

239 ducing inflammatory responses and regulating tolerogenic processes.

240 capacity of 1,25(OH)2D3 to imprint a similar tolerogenic profile in cells derived from diabetes-prone

241 1,25(OH)2D3 is able to imprint a phenotypic tolerogenic profile on DCs derived from both mouse strai

242 However, the drivers of this tolerogenic program are incompletely defined.

243 of the inhibitory coreceptor CD22, induce a tolerogenic program that selectively causes apoptosis in

244 antigens instruct DCs in an antigen-specific tolerogenic programming, enhancing Treg cells and reduci

245 l in potentiating the generation of DCs with tolerogenic properties by Act-A-iTreg cells.

246 referential delivery of antigens to DCs with tolerogenic properties implies a key role for this GC fu

247 boptimal glycemic control and assessed their tolerogenic properties in correlation with metabolic sta

248 COPD by examining the immunostimulatory and tolerogenic properties of pulmonary CD1c(+) DCs.

249 the resolution of a severe infection acquire tolerogenic properties that contribute to persistent imm

250 Because of their tolerogenic properties, regulatory T cells (Tregs) play

251 jects to lungs of patients with COPD confers tolerogenic properties.

252 merging during parasitic infections, display tolerogenic properties.

253 The liver has long been recognized as having tolerogenic properties.

254 val after liver replacement because of these tolerogenic properties.

255 Mer acted as a tolerogenic receptor in resting macrophages and during i

256 s critical determinants for the induction of tolerogenic regulatory CD4(+) T-cell differentiation.

257 key role for GCN2 signals in regulating the tolerogenic response to apoptotic cells and limiting aut

258 II MHC that can activate a proliferative or tolerogenic response.

259 upus erythematosus, has been shown to induce tolerogenic responses in dendritic cells and suppress TL

260 s in the skin and lungs but also homeostatic tolerogenic responses in the thymus and gut.

261 ar signaling pathways program DCs to mediate tolerogenic responses remains largely unexplored.

262 Failure to induce tolerogenic responses to allergens incites allergic infl

263 onists, and apoptotic cells can also promote tolerogenic responses via STING by activating immunoregu

264 Tolerogenic responses were dependent on induction of vit

265 teraction of innate and adaptive immunity in tolerogenic responses.

266 iphery, dendritic cells (DCs) play a crucial tolerogenic role, extending the maintenance of immune ho

267 ligands on the Ag-bearing cells, producing a tolerogenic signal involving Lyn and the proapoptotic fa

268 comes are due to a biochemical uncoupling of tolerogenic signaling, or simply a quantitative reductio

269 APCs will be presented without PD-L1 induced tolerogenic signalling, perhaps initiating disease.

270 B cells from BXD2 mice express low levels of tolerogenic signals and high levels of inflammatory sign

271 focused on the uptake of ACs by phagocytes, tolerogenic signals exposed by the ACs are much less wel

272 the surface of ACs to function as redundant tolerogenic signals in vitro and in vivo.

273 sting that a combination of inflammatory and tolerogenic signals promote c-Maf expression.

274 immunogenicity of gut antigens by delivering tolerogenic signals.

275 et resulted in increased numbers of CD103(+) tolerogenic splenic DCs, with a concomitant increase in

276 xposure to LPS, adenosine can supersede this tolerogenic state and drive IL-1beta production.

277 Unraveling how the reactive versus tolerogenic state is controlled might point toward novel

278 cute-phase conditions, induces a semimature, tolerogenic state on human monocyte-derived dendritic ce

279 hCG also retained dendritic cells in a tolerogenic state that is likely to contribute to both T

280 how STING-dependent DNA sensing can enhance tolerogenic states in tumors characterized by low antige

281 ng the plasticity of NK cells in response to tolerogenic stimuli.

282 physical disruption of cell-cell contacts a tolerogenic stimulus.

283 fer of ex vivo-generated immune-promoting or tolerogenic T cells to either enhance immunity or promot

284 jective measurements of the effectiveness of tolerogenic therapies, and to allow intelligent immunosu

285 Development of tolerogenic therapies, other than standard immune tolera

286 g of Treg suspensions generated for adoptive tolerogenic therapies.

287 l stages, offers a window of opportunity for tolerogenic therapy.

288 certain conditions, LSECs can switch from a tolerogenic to an immunogenic state and promote the deve

289 ed Tregs are a promising approach for future tolerogenic treatment of hemophilia A patients with inhi

290 pment of hESC-derived therapy, combined with tolerogenic treatments, as a sustainable alternative str

291 t mediates tissue damage and by promotion of tolerogenic Treg cells.

292 (Treg) cell commitment, resulting in a more tolerogenic Treg to conventional T cell ratio and protec

293 ce receptors, transcription factors, and the tolerogenic tryptophan-degrading enzyme indoleamine 2,3-

294 Cs presenting the gastric autoantigen remain tolerogenic under such conditions, demonstrating the rob

295 Tolerogenic vaccination required all three components, I

296 This study introduces a flexible format for tolerogenic vaccination that incorporates IFN-beta and n

297 d in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mi

298 evious JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mi

299 Tolerance induction was specific for the tolerogenic vaccine Ag PLP178-191 or myelin oligodendroc

300 An important question was whether GMCSF-NAg tolerogenic vaccines retained inhibitory activity within